Embedded Files
DelveInsight’s “IL-17 Inhibitors– Target Population, Competitive Landscape, and Market Forecast–2034” report delivers an in-depth understanding of the IL-17, historical and forecasted epidemiology as well as the IL-17 inhibitor market trends in the United States, EU4 (Germany, France, Italy, and Spain), and the United Kingdom, and Japan.
Unlock detailed insights into the Interleukin-17 (IL-17) Inhibitors Market by downloading the comprehensive report from DelveInsight @ Interleukin-17 (IL-17) Inhibitors Market
Key Takeaways from the Interleukin-17 (IL-17) Inhibitors Market Report
As per the analysis, the risk of autoimmune and inflammatory diseases increases with age and genetic factors, with Interleukin-17 (IL-17) Inhibitors offering targeted suppression of inflammation.
According to DelveInsight, the total diagnosed prevalent cases of psoriasis in the 7MM were ~15 million in 2024.
According to the National Psoriasis Foundation, psoriasis is predominantly observed in adults, accounting for maximum cases in the 7MM.
According to the American Academy of Dermatology, plaque psoriasis accounts for the majority of psoriasis cases, with erythrodermic psoriasis being less common.
The leading Interleukin-17 (IL-17) Inhibitors Companies such as MoonLake Immunotherapeutics, UCB Pharma, AstraZeneca/Bausch Health/Kyowa Kirin/LEO Pharma, Affibody Medical AB, SFA Therapeutics, DICE Therapeutics/Eli Lilly, and others.
Promising Interleukin-17 (IL-17) Inhibitors Drugs such as BIMZELX (bimekizumab), SILIQ (brodalumab), TALTZ (ixekizumab), COSENTYX (secukinumab), Sonelokimab, Izokibep, Simepdekinra (DC-853), SFA-002, and others.
Gain a competitive edge in the Interleukin-17 (IL-17) Inhibitors Market by exploring our in-depth analysis. Visit our website to access the full report and make informed strategic decisions @ Interleukin-17 (IL-17) Inhibitors Drugs Market
Interleukin-17 (IL-17) Inhibitors Epidemiology Segmentation in the 7MM
Total Cases of Selected Indications for IL-17 Inhibitor
Total Eligible Patient Pool of Selected Indications for IL-17 Inhibitor
Total Treated Cases of Selected Indications for IL-17 Inhibitor
Interleukin-17 (IL-17) Inhibitors Treatment Market The primary treatment for IL-17-related conditions includes lifestyle modifications, approved inhibitors, and targeted biologics. Recent advancements include the approval of BIMZELX (bimekizumab) by UCB in 2023, SILIQ (brodalumab) by AstraZeneca in 2017, TALTZ (ixekizumab) by Eli Lilly in 2016, and COSENTYX (secukinumab) by Novartis in 2015, which enhance treatment options for psoriasis, psoriatic arthritis, and ankylosing spondylitis. Focusing on the chronic and severe nature of these conditions, the treatment approach is comprehensive; blocking IL-17 pathways and controlling inflammation is the key treatment target.
Interleukin-17 (IL-17) Inhibitors Market Insights Interleukin-17 inhibitors are a serious, life-threatening condition with no cure, serving as a risk factor for numerous complications. While there is no established cure, diagnostic tools are available to identify inflammation, and treatment involves monoclonal antibodies and biologics, alongside conventional therapies. BIMZELX, the most innovative dual inhibitor, blocks both IL-17A and IL-17F for broader suppression.
Discover key developments and opportunities in the Interleukin-17 (IL-17) Inhibitors Market. Click here to learn more from DelveInsight's latest report @ Interleukin-17 (IL-17) Inhibitors Market Size
Interleukin-17 (IL-17) Inhibitors Marketed Drugs
BIMZELX (bimekizumab): UCB Pharma In October 2023, the US Food and Drug Administration approved BIMZELX (bimekizumab) for the treatment of adults with moderate-to-severe plaque psoriasis. BIMZELX is a humanized monoclonal antibody that selectively inhibits IL-17A and IL-17F, providing dual inhibition for enhanced anti-inflammatory effects.
SILIQ (brodalumab): AstraZeneca/Bausch Health/Kyowa Kirin/LEO Pharma In February 2017, the US FDA approved SILIQ (brodalumab) for the treatment of adults with moderate-to-severe plaque psoriasis. SILIQ is a human IL-17 Receptor A antagonist that blocks IL-17 signaling to reduce inflammation.
Interleukin-17 (IL-17) Inhibitors Emerging Drugs
Sonelokimab - MoonLake Immunotherapeutics Sonelokimab is a next-generation biologic targeting both IL-17A and IL-17F using a nanobody-based format. In January 2025, MoonLake announced the initiation of new clinical trials for sonelokimab in hidradenitis suppurativa and other conditions.
Izokibep - Affibody Medical AB Izokibep is a small-format IL-17A inhibitor designed for high potency and deep tissue penetration. In April 2025, Affibody reported positive Phase II results for izokibep in psoriatic arthritis.
Other novel emerging drugs in the Interleukin-17 (IL-17) Inhibitors treatment market in different clinical trial phases include - Simepdekinra (DC-853): DICE Therapeutics/Eli Lilly, SFA-002: SFA Therapeutics, and others.
Interleukin-17 (IL-17) Inhibitors Market Outlook The Interleukin-17 (IL-17) Inhibitors Market is a competitive landscape with targeted biologics entering the market. The autoimmune and inflammatory disease drugs market is moderately fragmented, with significant players launching novel inhibitors. The market competitors are developing not only novel therapies but also diagnostic tools for inflammation markers. The expansion of the healthcare sector and favorable regulatory support are fueling the growth of the interleukin-17 inhibitors market.
Download DelveInsight's Interleukin-17 (IL-17) Inhibitors Market report today and stay ahead in this rapidly evolving field. @ Interleukin-17 (IL-17) Inhibitors Clinical Trials
Scope of the Interleukin-17 (IL-17) Inhibitors Market Report
Coverage- Global
Study Period- 2020-2034
Interleukin-17 (IL-17) Inhibitors Companies- MoonLake Immunotherapeutics, UCB Pharma, AstraZeneca/Bausch Health/Kyowa Kirin/LEO Pharma, Affibody Medical AB, SFA Therapeutics, DICE Therapeutics/Eli Lilly, and others.
Interleukin-17 (IL-17) Inhibitors Drugs- BIMZELX (bimekizumab), SILIQ (brodalumab), TALTZ (ixekizumab), COSENTYX (secukinumab), Sonelokimab, Izokibep, Simepdekinra (DC-853), SFA-002, and others.
Interleukin-17 (IL-17) Inhibitors Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
Interleukin-17 (IL-17) Inhibitors Unmet Needs, KOL's views, Analyst's views, Interleukin-17 (IL-17) Inhibitors Market Access and Reimbursement
Download the report to understand which factors are driving Interleukin-17 (IL-17) Inhibitors Market Trends @ Interleukin-17 (IL-17) Inhibitors Market Trends
Table of Content
1 Key Insights
2 Report Introduction
3 Executive Summary of Interleukin-17 (IL-17) Inhibitors
4 Key Events
5 Epidemiology and Market Forecast Methodology of IL-17 Inhibitors
6 IL-17 Inhibitors Market Overview at a Glance in the 7MM
7 IL-17 Inhibitors: Background and Overview
8 Target Patient Pool
9 Marketed Products of IL-17 Inhibitors
10 Emerging Therapies of IL-17 Inhibitors
11 IL-17 Inhibitor: Seven Major Market Analysis
12 Market Access and Reimbursement of IL-17 Inhibitors
13 SWOT Analysis of IL-17 Inhibitors
14 KOL Views of IL-17 Inhibitors
15 Unmet Needs of IL-17 Inhibitors
16 Appendix
17 DelveInsight Capabilities
18 Disclaimer
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Contact Us
Kanishk
Page updated
Google Sites
Report abuse